Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3040% below fair value

$19.03+0.06 (+0.32%)

Close on Nov 13, 2026Market cap $1.37BP/E 9.7Yield –

Innoviva EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Innoviva's EV/EBITDA was 6.5× on Nov 11, 2026, against 8.4× a year earlier. Over the last 5 years it ranged from 2.5× to 8.8×, with a median of 4.8×.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	6.5×	−1.1
2025	Dec 31, 2025	7.6×	+5.1
2023	Jan 31, 2023	2.5×	−0.1
2022	Dec 30, 2022	2.6×	−1.5
2021	Dec 31, 2021	4.2×	+0.4
2020	Dec 31, 2020	3.7×	−2.1
2019	Dec 31, 2019	5.8×	−3.8
2018	Dec 31, 2018	9.7×	−3.7
2017	Dec 29, 2017	13.3×	−4.6
2016	Dec 30, 2016	17.9×	−43.9
2015	Dec 31, 2015	61.8×	−363.7
2012	Jul 31, 2012	425.5×	–